Product Innovation Board Analysis

Product innovation in the insurance sector has become a critical boardroom issue, shaped by rapidly evolving policyholder expectations, intensifying regulatory scrutiny, and the emergence of complex risk categories such as cyber, climate, and pandemic exposures. Insurers are piloting embedded insurance, usage-based models, and novel distribution partnerships—including digital MGAs and broker alliances—to capture growth and respond to shifting demand. However, the pace, quality, and governance of these efforts vary widely, exposing insurers to uneven risk, capital, and regulatory profiles.

Boards are under mounting pressure to balance growth ambitions and differentiation with robust risk management, capital discipline, and regulatory compliance. Regulatory authorities are sharpening their focus on product governance, customer outcomes, and the processes underpinning innovation. This includes explicit expectations for board oversight, documented risk appetite, and demonstrable alignment with fair customer outcomes.

The regulatory lens now extends beyond product outcomes to the governance, controls, and assurance mechanisms supporting innovation.

A persistent misjudgment is the assumption that innovation is inherently value-accretive or that digital and embedded offerings will automatically achieve market adoption. In reality, innovation can introduce new risks, operational complexity, and heightened regulatory scrutiny—particularly if product governance, risk assessment, or customer impact analysis is inadequate. Boards must require management to provide clear, evidence-based assurance that product innovation aligns with strategy, is subject to rigorous controls, and is monitored for both commercial and conduct outcomes post-launch.

The urgency for boards is clear: regulators are scrutinizing not only the outcomes of product innovation but also the governance processes that underpin them. Decision pressure is intensifying around capital allocation between new products and legacy portfolios, managing the risk of regulatory challenge or consumer harm, and maintaining institutional credibility with investors and supervisors.

Boards must insist on clear, evidence-based reporting on product innovation, challenge narrative assertions, and require management to demonstrate that innovation delivers sustainable value without compromising risk, capital, or conduct standards. Explicit board oversight, committee accountability, and management evidence are now non-negotiable for regulatory credibility and sustainable competitive advantage.

• Product innovation is a board-level issue due to its direct impact on growth, risk profile, capital allocation, and regulatory posture. - Regulatory scrutiny is intensifying, with a focus on product governance, fair customer outcomes, transparent disclosures, and explicit board and committee accountability. - Management assertions about innovation must be substantiated by evidence on adoption rates, risk controls, customer impact, and regulatory feedback, including claims experience, complaints, and conduct risk metrics.

• Boards must weigh capital allocation to new products against the potential for unintended risk, consumer harm, or regulatory challenge, ensuring alignment with risk appetite and solvency requirements. - Effective oversight requires escalation of product innovation to the board agenda, with structured reporting, independent assurance, and robust challenge on key metrics, including capital consumption, reserving adequacy, and customer outcomes.

The board’s central thesis should be that product innovation is neither inherently positive nor negative; its value depends on disciplined execution, strategic alignment, and credible risk and conduct controls. Innovation can drive growth and differentiation, but it can also expose the insurer to new risks, operational strain, and regulatory challenge if not properly governed. The board must treat product innovation as both a strategic and a risk management issue, not merely a commercial or technical opportunity.

A credible board position requires management to demonstrate that product innovation is subject to the same rigor as other core insurance activities: clear business cases, defined risk appetite, robust governance, and transparent customer outcomes monitoring. The board should not accept narrative assertions about market opportunity or digital transformation without supporting evidence on adoption, retention, claims experience, risk, and regulatory feedback.

Where innovation creates new or untested exposures, the board must require management to demonstrate that controls, disclosures, and remediation plans are in place and effective, and that capital allocation is justified by robust scenario analysis and risk-adjusted returns.

Boards and executives may misinterpret product innovation as primarily a commercial or technical matter, underestimating its governance, capital, and regulatory implications. A frequent error is prioritizing speed to market or digital enablement while neglecting rigorous product governance, risk assessment, and post-launch monitoring. This can result in unintended consumer harm, regulatory challenge, or capital strain if new products underperform or introduce unanticipated risks—especially in lines such as cyber, parametric, or climate-linked insurance where loss experience is less predictable.

This misreading is significant because regulators are increasingly focused on the processes and controls behind product innovation, not just outcomes. Supervisors expect boards to have direct oversight of product governance, including evidence that new offerings align with risk appetite, deliver fair outcomes, and are subject to transparent disclosures. Failure to meet these expectations can result in regulatory intervention, reputational damage, or capital penalties, including increased reserving requirements or restrictions on new business.

Boards should require management to demonstrate that product innovation is supported by documented governance processes, clear risk assessments, and ongoing monitoring of customer outcomes and regulatory feedback. The board should insist on evidence that new products are not only commercially viable but also compliant with regulatory expectations and aligned with the insurer’s risk and conduct standards. Committee accountability—particularly for risk, audit, and conduct committees—must be explicit, with clear escalation protocols for emerging risks or control failures.

The insurance sector is undergoing significant transformation in product development, driven by evolving policyholder expectations, digital transformation, and the emergence of new risk categories. Insurers are piloting embedded insurance models, usage-based products, and new distribution partnerships—including digital MGAs, brokers, and insurtech platforms—to capture growth and respond to changing demand. The effectiveness of these innovations varies, with some markets and segments advancing more rapidly than others, and with varying levels of risk and capital intensity.

Regulatory authorities in major jurisdictions are responding with increased scrutiny of product innovation, focusing on fair customer outcomes, transparency, and risk management. Supervisors expect insurers to have robust product governance frameworks, clear disclosures, and evidence that new products do not create unintended consumer harm. Regulatory initiatives such as sandboxes, thematic reviews, and conduct risk assessments are being used to test and monitor innovation, but these also raise expectations for board oversight, documented governance, and committee accountability.

Internally, insurers must balance the need for speed and differentiation with prudent risk management, capital allocation, and regulatory compliance. Product innovation can strain existing operating models, data infrastructure, and control frameworks, especially where new risks or distribution channels are involved. Boards must remain alert to the potential for operational complexity, control gaps, and misalignment with risk appetite as innovation accelerates.

The impact on reserving, reinsurance arrangements, and solvency capital requirements must be explicitly considered in all product innovation initiatives.

Boards must demand robust, verifiable evidence from management to ensure that product innovation is governed with the same rigor as other core insurance activities. The following categories of evidence are essential for effective board oversight and committee accountability: 1. Product Launch Volume and Performance - Detailed reporting on the number and type of new product launches over the past 24 months, including embedded, usage-based, and digitally distributed products, with breakdowns by line of business and distribution channel (e.g., broker, MGA, direct).

• Analysis of commercial impact, including gross written premium, loss ratios, margin performance, and capital consumption. - Identification of products with high launch volume but low adoption or poor performance, with root cause analysis and remediation actions, including impact on reserving and reinsurance. 2.

Customer Adoption, Retention, and Outcome Metrics - Segmented data on policyholder adoption and retention rates for innovative products, broken down by channel, demographic, and distribution partner. - Monitoring of customer complaints, claims experience, and feedback specific to new products, with conduct risk and complaints analysis. - Evidence of fair customer outcomes, including analysis of claims ratios, lapse rates, customer satisfaction scores, and conduct risk indicators.

1. 01Internal Audit and Risk Reports - Independent assurance reports on the effectiveness of product governance, control frameworks, and post-launch monitoring, with explicit coverage of underwriting, pricing, and claims processes. - Documentation of control failures, unresolved risk issues, and management responses, including escalation to the risk and audit committees.

- Evidence of regular testing of controls and escalation of significant findings to the board and relevant committees. 4. Regulatory Feedback and Thematic Findings - Copies of regulatory correspondence, thematic review findings, and remediation requirements related to product innovation, including conduct risk and customer outcomes.

• Evidence of timely and effective management response to regulatory feedback, including escalation protocols to the board and relevant committees. - Analysis of regulatory trends and emerging themes relevant to product governance, capital adequacy, and conduct risk. 5.

Product Governance Documentation - Comprehensive documentation of product governance processes, including risk assessments, board and committee approvals, and customer outcome monitoring. - Evidence of alignment with stated risk appetite, capital constraints, and solvency requirements. - Documentation of decision rights, committee accountabilities, and escalation procedures for emerging risks or control failures.

1. 01External Benchmarking and Market Intelligence - Comparative analysis of new product performance against peer insurers and market standards, including loss ratios, claims experience, and customer outcomes. - Identification of areas where internal performance lags the market, with targeted action plans for improvement.

- Use of external market intelligence to validate internal assumptions and challenge management narratives, including benchmarking of capital allocation and risk-adjusted returns. 7. Capital Allocation and Profitability Analysis - Detailed analysis of capital allocated to new product initiatives, including expected versus actual profitability, capital consumption, and impact on overall capital adequacy and solvency.

• Evidence that capital allocation decisions are based on clear business cases, risk appetite alignment, and robust scenario analysis, including stress testing for adverse claims or regulatory scenarios. - Monitoring of capital strain, margin erosion, or reserving shortfalls resulting from underperforming products. 8.

Post-Launch Reviews and Remediation Actions - Structured post-mortem reviews of challenged or withdrawn products, with documented lessons learned and remediation actions, including impact on customer outcomes and regulatory posture. - Evidence that learning from failures is incorporated into future product governance and innovation processes, with committee oversight. - Tracking of repeat issues or systemic weaknesses in product development and governance, with escalation to the board and relevant committees.

Boards should expect regular, structured reporting from management, including quantitative data, controls testing results, audit findings, and updates on regulatory correspondence. Independent validation and external benchmarking should be incorporated to ensure a comprehensive view of product innovation risks and opportunities. The board should also require evidence of effective escalation and accountability for emerging risks or control failures, with clear committee oversight.

Product innovation introduces a spectrum of risks and control challenges that require direct and ongoing board and committee oversight: 1. Product Governance and Conduct Risk - Weak product governance can result in consumer harm, regulatory challenge, and reputational damage. Boards must ensure that management provides documented frameworks, board and committee approvals, and evidence of outcome monitoring for all new products.

• Conduct risk is heightened where product features, disclosures, or distribution practices are novel or complex. Boards should require evidence of conduct risk assessments and customer impact analysis for all innovative offerings, with explicit committee accountability. 2.

Risk Appetite and Capital Allocation - Misalignment between product innovation and the insurer’s risk appetite or capital constraints can lead to capital strain, volatility, or breach of risk limits. Boards should require risk assessments, capital impact analysis, and confirmation of alignment with stated risk appetite and solvency requirements for all new products. - Capital allocation to innovation must be disciplined, with clear business cases, scenario analysis, and robust challenge of management assumptions, overseen by the risk and finance committees.

1. 01Operational Complexity and Control Effectiveness - New product structures, distribution models, and technology platforms can introduce operational complexity and increase the risk of errors, fraud, or process failures. Boards should require regular control testing, internal audit reviews, and evidence of effective remediation, with escalation to the audit committee.

- The board should challenge management on the adequacy of data infrastructure, control frameworks, and talent to support innovation at scale, ensuring that the operating model is fit for purpose. 4. Customer Outcomes and Remediation - Insufficient monitoring of customer outcomes or delayed remediation for new products can result in regulatory and reputational consequences.

Boards should expect regular reporting on customer outcome metrics, complaints analysis, and evidence of timely remediation actions, with oversight by the conduct and risk committees. - The board should require management to demonstrate that customer needs are understood, outcomes are monitored, and remediation is swift where issues arise, including for vulnerable policyholders. 5.

Regulatory Compliance and Supervisory Expectations - Regulatory non-compliance or delayed response to supervisory expectations carries the risk of fines, sanctions, or business restrictions. Boards must require management to provide regulatory correspondence, compliance attestations, and evidence of timely remediation, with escalation to the board and relevant committees. - The board should ensure that regulatory themes and emerging risks are escalated promptly and addressed with appropriate action plans, maintaining regulatory credibility.

1. 01Assurance, Escalation, and Accountability - Over-reliance on narrative assertions about innovation without supporting data can lead to poor decision-making and lack of accountability. Boards should insist on quantitative performance data, external benchmarking, and independent validation, with committee oversight.

- The board should require clear documentation of decision rights, committee accountabilities, and escalation protocols for emerging risks or control failures. 7. Learning from Failure - Failure to learn from challenged or withdrawn product launches erodes institutional credibility and increases the risk of repeat failures.

Boards should require structured post-launch reviews, lessons learned documentation, and evidence of process improvement, with oversight by the risk and audit committees.

Product innovation presents significant trade-offs for capital allocation, operating model design, governance, and regulatory posture. Boards must weigh the potential for sustainable value creation against the risk of eroding margins, increasing volatility, or breaching risk appetite and solvency requirements. 1.

Capital Allocation and Portfolio Management - Allocating capital to new products can drive growth and differentiation, but also introduces the risk of capital strain if products underperform or require remediation. Boards must ensure that capital allocation decisions are based on robust business cases, scenario analysis, and alignment with risk appetite and solvency requirements.

- The board should require regular review of the balance between investment in innovation and the management of legacy portfolios, with clear criteria for reallocating capital in response to performance or emerging risks, overseen by the finance and risk committees. 2. Operating Model and Control Environment - The operating model must adapt to support innovation, including changes to data infrastructure, control frameworks, and talent requirements.

Boards should challenge management to demonstrate that the operating model is fit for purpose and that innovation does not outpace the insurer’s capacity for risk management and compliance. - The board should require evidence of investment in data, technology, and talent to support safe and effective innovation, with oversight by the audit and risk committees. 3.

Governance and Regulatory Posture - Governance and regulatory posture are under heightened scrutiny as supervisors expect clear board oversight, documented risk appetite, and evidence of fair customer outcomes. Boards must ensure that product innovation is subject to the same rigor as other core insurance activities, with transparent reporting, independent assurance, and escalation of emerging risks. - The board should require regular updates on regulatory themes, supervisory expectations, and the insurer’s response to emerging risks, with committee accountability.

1. 01Customer Outcomes and Institutional Trust - Customer outcomes are central to the board’s oversight of product innovation. New products must deliver value to policyholders without creating unintended harm or complexity.

Boards should require evidence that customer needs are understood, outcomes are monitored, and remediation is swift where issues arise, including for vulnerable customers. - Sustainable innovation depends on maintaining trust with policyholders, regulators, and investors. The board should ensure that customer outcomes are a standing agenda item and that management is held accountable for delivering fair and transparent outcomes, with oversight by the conduct and risk committees.

To ensure effective oversight and control of product innovation, management should:

• Mandate formal product governance processes for all new product initiatives, including board and committee-level approval, documented risk assessments, and clear decision rights. - Require regular, structured reporting on the performance, adoption, claims experience, and customer outcomes of innovative products, segmented by channel, demographic, and distribution partner. - Commission independent internal audit reviews of product governance, controls, and post-launch monitoring for all new offerings, with findings escalated to the board and relevant committees.

• Conduct structured post-mortem reviews of challenged or withdrawn products, with documented lessons learned and remediation actions incorporated into future processes, overseen by the risk and audit committees. - Allocate capital to new product initiatives based on clear business cases, risk appetite alignment, profitability analysis, and solvency impact, with regular review of capital consumption, margin performance, and reserving adequacy.

• Update the operating model to support innovation, including investment in data infrastructure, control frameworks, and talent development, with explicit committee oversight. - Establish a regulatory heatmap and escalation protocol for supervisory feedback, ensuring timely board and committee awareness and response to regulatory themes and emerging risks. - Ensure that all product innovation initiatives are subject to independent validation, external benchmarking, and robust challenge of management assumptions, with committee accountability.

The board must approach product innovation as a strategic, capital, and conduct risk, not merely a commercial opportunity. Effective oversight requires disciplined governance, clear evidence of alignment with risk appetite and solvency requirements, and transparent reporting on customer outcomes and regulatory feedback. Product innovation should be a standing agenda item, with regular updates on performance, risk, capital allocation, and regulatory themes, and with explicit committee accountability.

Management must be held accountable for providing evidence-based reporting, independent assurance, and documented learning from both successes and failures. The board should not accept narrative assertions or unsupported optimism about innovation; every new product initiative must be subject to rigorous challenge and scrutiny, with clear escalation to the board and relevant committees.

The board should not accept from management any position that treats product innovation as exempt from core governance, risk, capital, or conduct standards. Assertions about market opportunity, digital transformation, or customer demand must be supported by hard evidence, independent validation, and clear accountability for outcomes, including capital allocation and reserving adequacy. Where evidence is lacking or risks are emerging, the board must require immediate escalation and remediation, with committee oversight.

Ultimately, the board’s role is to ensure that product innovation delivers sustainable value, supports fair customer outcomes, and maintains the insurer’s regulatory credibility, capital strength, and solvency. This requires a mature, evidence-led approach to oversight, robust challenge of management, and a clear commitment to learning and continuous improvement. Only by embedding these disciplines and ensuring explicit committee accountability can boards ensure that product innovation is a source of competitive advantage rather than a vector for risk or regulatory intervention.